AZD4625 is a Potent and Selective Inhibitor of KRAS(G12C)

AZD4625 is a potent, selective, and orally bioavailable inhibitor of oncogenic KRAS(G12C) as demonstrated in cellular assays and in vivo in preclinical cell line–derived and patient-derived xenograft models. In vitro and cellular assays have shown selective binding and inhibition of the KRAS(G12C) m...

Descripción completa

Detalles Bibliográficos
Autores principales: Chakraborty, Atanu, Hanson, Lyndsey, Robinson, David, Lewis, Hilary, Bickerton, Sue, Davies, Michael, Polanski, Radoslaw, Whiteley, Rebecca, Koers, Alex, Atkinson, James, Baker, Tamara, del Barco Barrantes, Ivan, Ciotta, Giovanni, Kettle, Jason G., Magiera, Lukasz, Martins, Carla P., Peter, Alison, Wigmore, Eleanor, Underwood, Zoe, Cosulich, Sabina, Niedbala, Michael, Ross, Sarah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Small Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9538594/
https://www.ncbi.nlm.nih.gov/pubmed/35930755
http://dx.doi.org/10.1158/1535-7163.MCT-22-0241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9538594/
https://www.ncbi.nlm.nih.gov/pubmed/35930755
http://dx.doi.org/10.1158/1535-7163.MCT-22-0241

Ejemplares similares